Board of Directors

Dr Amrein is a seasoned healthcare executive with more than 25 years of leadership and international experience across a variety of therapeutic areas. Prior to joining Stallergenes Greer, he was Managing Director and member of the Global Leadership Team at Advanced Clinical, a leading global contract research organisation. Dr. Amrein previously held positions of increasing responsibility, notably at Novartis, Abbott and Shire Takeda, where he accrued significant expertise in P&L leadership, specialising in commercial expansions, market entries, product launches, transformations, acquisitions, and integrations.

Dr Amrein is Swiss and holds a PhD in Health Economics, Evidence Based Medicine and Quality of Life for Rare Diseases from the University of Southern Queensland (Australia), an MBA from INSEAD (France) and a Master of Physics from ETH Zurich (Switzerland).

In this role, she helped to lead the acquisitions of Radius Health and Paratek Pharmaceuticals. She sits on the Board of both companies, as well as that of Corium.

Nythia Desikan was the Chief Operating Officer of SionnaTherapeutics, a company focused on development of novel therapies for Cystic Fibrosis. Prior to this role, she was the Chief Commercial Officer of Rhythm Pharmaceuticals from clinical-stage start-up to approval of their first product. She joined Rhythm from Biogen, where in her 5-year tenure, she oversaw the launches of Alprolix® and Eloctate®. While with Biogen, Nithya Desikan also led the Tecfidera® global business and cross-functional strategies for long-term value creation as Vice President and Asset Executive. 

She began her career with 12 years at Johnson & Johnson Company, launching brands in the US and abroad including: Xarelto®, Levaquin®, Topamax®, Ultracet®, and Velcade®. She holds a BS in Material Science Engineering from the University of Florida.

Full-time roles include connection to a variety of organisations within Life Sciences, including Biotech, Healthcare IT, and Professional Services.  Steven Rotman joined the B-FLEXION team in 2022 and has been an active board member and advisor across the spectrum of the healthcare platform; Therapeutics, Diagnostics, Provider Practice Management, and others.

Before joining B-FLEXION, he was the Chief People & Engagement Officer at Karyopharm Therapeutics, a publicly-traded pharmaceutical organisation dedicated to the advancement of therapies in the oncology space. He also spent 10 years as the Vice President of Human Resources at NaviNet, an organisation with a commitment to link payors and providers in the US healthcare market. In addition to these full-time roles, he also serves on the President’s advisory board of the Whittier Street Health Center, a community-based provider serving tens of thousands of patients in one of the most underserviced neighborhoods in the region.

Steven Rotman compliments his professional experiences with a Bachelor’s Degree in Interpersonal Communication from the University of New Hampshire and a Master’s of Science Degree in Human Capital Management from Suffolk University.  There are also a number of local, charitable, and industry organisations that count him as a board member, advisor, and volunteer.

He is Director and Head of Legal at BEMIDO SA (Swiss branch of the B-FLEXION Group), where he leads global legal and compliance activities, including corporate governance, regulatory compliance, anti-money laundering oversight, litigation management, and complex commercial and transactional contract negotiations. He brings a pragmatic, international, and business-focused approach to legal and governance advisory.

He advises senior management and boards on legal risk, structuring, and strategic matters, and serves as a board member or observer for entities in multiple jurisdictions. He also provides governance oversight for private philanthropic foundations and trusts. 

.Frédéric Boder holds a Geneva Bar qualification and a master’s degree in European law from the Université libre de Bruxelles.